Ronald J. Scheff, M.D.

Medical Oncology
Ronald Scheff

I derive tremendous satisfaction from caring for cancer patients, and enjoy being part of an outstanding team at Weill-Cornell. The emphasis of my practice is on the treatment of lung cancer, primary brain tumors, and breast cancer. I also serve as Director of Fellowship Training for our department. In this capacity I am intimately involved in teaching and mentoring future medical oncologists and hematologists.

Following completion of an undergraduate degree in Biology at Yale University, Dr. Scheff obtained his medical degree at Columbia University College of Physicians and Surgeons.

He completed a three-year residency in Internal Medicine at the New England Deaconess Hospital in Boston, and then returned to New York for three years of fellowship training in Medical Oncology and Hematology at Memorial Sloan-Kettering Cancer Center.

For a number of years Dr. Scheff practiced medical oncology and hematology at the faculty practice of Staten Island University Hospital, where he was an integral part of their lung, brain, and breast cancer programs. He joined the faculty at Weill Medical College of Cornell University in 2006.

Insurances

Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please feel free to contact this physician or this physician's practice as they may have individual contracts not included on this site.

  • AETNA [HMO]
  • AETNA [PPO]
  • AETNA [Medicare]
  • Aetna - Weill Cornell [POS]
  • Affinity Essential
  • Affinity Health Plan
  • Blue Priority Network
  • CIGNA
  • Emblem Select Care
  • Empire Blue Cross/Blue Shield [Pathway X]
  • Empire Blue Cross/Blue Shield [Pathway X Enhanced]
  • Empire Blue Cross/Blue Shield [PPO]
  • Empire Blue Cross/Blue Shield [EPO]
  • Empire Blue Cross/Blue Shield [HMO]
  • Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • Fidelis Care
  • GHI [CBP]
  • Health First
  • Health Insurance Plan of NY (HIP) [Medicare]
  • Health Insurance Plan of NY (HIP)
  • Health Insurance Plan of NY (HIP) [Medicaid]
  • Health Plus - Amerigroup [CHP]
  • Health Plus - Amerigroup
  • Health Republic
  • Medicare [Medicare]
  • Oscar
  • Oxford Health Plans [Liberty]
  • Oxford Health Plans [Medicare Advantage]
  • Oxford Health Plans [Freedom]
  • Rockefeller University - CoreSource
  • UHC Compass
  • United Empire
  • United Health Care [Medicare]
  • United Health Care
  • United Health Care [Community Plan]
  • VNSNY CHOICE Medicare [Medicare]
  • VNSNY CHOICE Medicare [HMO]

Publications

Articles:

Scheff, Ronald J. Breast cancer and the new taxanes: focus on nab-paclitaxel. Community Oncology 5(7), Supplement 8, 2008: pp 7-13.

Hayes RL, Arbit E, Odaimi M, Pannullo S, Scheff R, Kravchinskiy D, Zaroulis C. Adoptive cellular immunotherapy for the treatment of malignant gliomas. Critical Rev Hematol/Oncol 39:31-42, 2001.

Huang Y, Hayes RL, Wertheim S, Arbit E, Scheff R. Treatment of refractory recurrent malignant glioma with adoptive cellular immunotherapy: a case report. Critical Rev Hematol/Oncol 57:17-23, 2001.

Editorial:

Scheff R. Fulvestrant offers an attractive treatment option for postmenopausal breast cancer.

Community Oncology 4(4):231-2, 2007.

Abstracts:

V. S. Blinder, M. Mahadeo, L. T. Vahdat, H. T. Gold, I. De Melo-Martin, M. K. Hayes, R. J. Scheff, A. Moore, E. Chuang and M. Mazumdar. Ethnicity and return to work in breast cancer survivors: An exploratory qualitative study. Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition).

Vol 26, No 15S (May 20 Supplement), 2008: 20532.

Scheff R, Maslak P, Jakubowski A. Approaches in the treatment of relapsed (rel) versus refractory (ref) acute myelogenous leukemia (AML). Proceedings of ASCO, 1995.

Huang Y, Hayes RL, Wertheim S, Scheff R, Arbit E. Treatment of refractory recurrent malignant glioma with adoptive cellular immunotherapy. American College of Physicians

National Competition, October 1999, Amer Soc of Internal Med, 2000.

Huang Y, Hayes RL, Wertheim S, Scheff R, Arbit E. Treatment of refractory recurrent malignant glioma with adoptive cellular immunotherapy. American College of Physicians

Local Competition, November 1999. Selected for poster presentation at the Associates Meeting Downstate Competition, New York, NY, April, 2000 [First place winner Research

category].

Huang Y, Hayes RL, Wertheim S, Arbit E, Scheff R. Treatment of refractory malignant glioma with adoptive immunotherapy: a case report. Poster presentation at the International

Conference on Advances in Cancer Immunotherapy, Cell-based Therapies session, Princeton, NJ, March 2000.

Hayes RL, Lazaro L, Odaimi M, Scheff R, Burton J. Immunologic monitoring of peripheral blood changes in patients with stage IV malignant melanoma or renal cell cancer treated with

sequential recombinant human GM-CSF (Leukine), interleukin-2 (IL-2, Proleukin) and PEG-interferon a2b (PEG-IFN, PEG-Intron) on a phase I/II clinical trial. Proceedings of Amer

Assoc Canc Res, 2003.

Hayes RL, Serventi J, Odaimi M, Scheff R, Zaroulis CG, Silverman P, Grosman I, Lederman G, Pannullo S. Synergistic efficacy of sequential fractionated stereotactic radiosurgery plus paclitaxel (FSRS T) and adoptive cellular immune therapy (ITX) using interleukin-2 and activated killer cells (LAK). Proceedings of Amer Assoc Canc Res, 2003.

Burton JD, El-Sayah D, Dib E, Badine E, Forte F, Terjanian T, Odaimi M, Vesoniaraki M, Lowry J, Scheff R. Phase I/II trial of standard-dose carboplatinum/gemcitabine escalating doses of celexicob for 1st-line treatment of stage IIIB/IV NSCLC. Proceedings of ASCO, 2003.

Letter:

Scheff RJ, Rolla AR. The eosinophilia-myalgia syndrome [letter]. Ann Intern Med 112(12): 964-5, 1990.

Honors and Awards

New York State Regents Scholarship for the Professional Study of Medicine, 1984-88.

Commendation letter for teaching excellence, Staten Island University Hospital,1999.